Oculis Holding AG (OCS) Depreciation & Amortization (CF) (2022 - 2026)

Oculis Holding AG's (OCS) quarterly Depreciation & Amortization (CF) came in at $196658.7 in Q1 2026, up 43.75% year-on-year from $136806.8 in Q1 2025, and down 0.52% quarter-over-quarter from $197684.8 in Q4 2025.

Oculis Holding AG (OCS) Depreciation & Amortization (CF) (2022 - 2026) Analysis & Trends

Oculis Holding AG's Depreciation & Amortization (CF) history runs 5 years deep, the most recent figure standing at $196658.7 for Q1 2026.

  • On a quarterly basis, Depreciation & Amortization (CF) rose 43.75% year-over-year to $196658.7 in Q1 2026; TTM through Mar 2026 was $720851.8, a 39.89% increase from a year earlier, with the FY2025 full-year figure at $658546.2, up 42.7% from the prior year.
  • Depreciation & Amortization (CF) declined to $196658.7 in Q1 2026 per OCS's latest filing, from $197684.8 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $207604.4 in Q4 2022 and bottomed at $33134.6 in Q3 2022.
  • The 5-year median for Depreciation & Amortization (CF) is $136491.6 (2025), against an average of $125414.5.
  • Biggest YoY gain for Depreciation & Amortization (CF) was 149.43% in 2023; the steepest drop was 59.82% in 2023.
  • Year by year, Depreciation & Amortization (CF) stood at $207604.4 in 2022, then plunged by 59.82% to $83424.2 in 2023, then soared by 66.94% to $139265.7 in 2024, then soared by 41.95% to $197684.8 in 2025, then retreated by 0.52% to $196658.7 in 2026.
  • Per Business Quant, the three latest OCS Depreciation & Amortization (CF) figures stand at $196658.7 (Q1 2026), $197684.8 (Q4 2025), and $190016.6 (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Depreciation & Amortization (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - 196,658.72
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 41.14 Mn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn 55.90 Mn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn 123.20 Mn
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn -
9 Revolution Medicines 37.37 Bn 37.37 Bn - 2.20 Mn
10 Alnylam Pharmaceuticals 36.08 Bn 33.07 Bn 959.66 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2026 196,658.72
Mar 31, 2026 196,658.72
Dec 31, 2025 197,684.83
Dec 31, 2025 197,684.83
Sep 30, 2025 190,016.65
Sep 30, 2025 190,016.65
Jun 30, 2025 136,491.60
Jun 30, 2025 136,491.60
Mar 31, 2025 136,806.82
Mar 31, 2025 136,806.82
Dec 31, 2024 139,265.67
Dec 31, 2024 139,265.67
Sep 30, 2024 140,813.28
Sep 30, 2024 140,813.28
Jun 30, 2024 98,415.62
Jun 30, 2024 98,415.62
Mar 31, 2024 83,634.81
Mar 31, 2024 83,634.81
Dec 31, 2023 83,424.23
Dec 31, 2023 83,424.23